Quest Partners LLC Acquires New Shares in United Therapeutics Co. (NASDAQ:UTHR)

Quest Partners LLC bought a new stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 3,500 shares of the biotechnology company's stock, valued at approximately $770,000.

Other hedge funds have also recently made changes to their positions in the company. International Assets Investment Management LLC increased its stake in shares of United Therapeutics by 13,769.2% in the fourth quarter. International Assets Investment Management LLC now owns 9,015 shares of the biotechnology company's stock valued at $1,982,000 after buying an additional 8,950 shares during the period. DekaBank Deutsche Girozentrale lifted its holdings in United Therapeutics by 54.4% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 94,643 shares of the biotechnology company's stock valued at $20,617,000 after buying an additional 33,338 shares during the period. Nordea Investment Management AB boosted its position in United Therapeutics by 155.2% during the fourth quarter. Nordea Investment Management AB now owns 38,698 shares of the biotechnology company's stock valued at $8,427,000 after acquiring an additional 23,532 shares during the last quarter. BNP Paribas Financial Markets grew its stake in United Therapeutics by 90.3% during the fourth quarter. BNP Paribas Financial Markets now owns 55,481 shares of the biotechnology company's stock worth $12,200,000 after purchasing an additional 26,325 shares during the period. Finally, Duality Advisers LP boosted its stake in United Therapeutics by 56.1% during the fourth quarter. Duality Advisers LP now owns 15,642 shares of the biotechnology company's stock worth $3,440,000 after acquiring an additional 5,622 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Price Performance

Shares of UTHR traded up $1.25 during mid-day trading on Wednesday, reaching $276.44. 495,230 shares of the stock traded hands, compared to its average volume of 459,145. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04. United Therapeutics Co. has a 1 year low of $204.44 and a 1 year high of $279.98. The company has a market cap of $12.26 billion, a price-to-earnings ratio of 13.07 and a beta of 0.54. The firm has a fifty day moving average price of $245.78 and a 200 day moving average price of $233.38.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, beating the consensus estimate of $5.63 by $0.54. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The firm had revenue of $677.70 million for the quarter, compared to analysts' expectations of $620.31 million. During the same quarter last year, the firm posted $4.86 EPS. The company's revenue was up 33.7% compared to the same quarter last year. As a group, equities research analysts predict that United Therapeutics Co. will post 24.2 earnings per share for the current year.

Insider Transactions at United Therapeutics

In related news, Director Christopher Patusky sold 1,680 shares of the stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $224.00, for a total value of $376,320.00. Following the transaction, the director now owns 4 shares of the company's stock, valued at $896. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, Director Martine A. Rothblatt sold 1,468 shares of the firm's stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $275.85, for a total transaction of $404,947.80. Following the transaction, the director now directly owns 130 shares of the company's stock, valued at $35,860.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Christopher Patusky sold 1,680 shares of the business's stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $224.00, for a total value of $376,320.00. Following the completion of the sale, the director now directly owns 4 shares of the company's stock, valued at approximately $896. The disclosure for this sale can be found here. Insiders have sold 155,208 shares of company stock valued at $37,436,641 in the last quarter. Insiders own 12.50% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on UTHR shares. Oppenheimer lifted their price target on shares of United Therapeutics from $375.00 to $400.00 and gave the company an "outperform" rating in a research report on Thursday, May 2nd. Leerink Partnrs restated an "outperform" rating on shares of United Therapeutics in a report on Monday, February 5th. StockNews.com raised shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 16th. HC Wainwright reaffirmed a "buy" rating and issued a $300.00 price target on shares of United Therapeutics in a report on Thursday, May 2nd. Finally, Wedbush reissued an "outperform" rating and set a $308.00 price objective on shares of United Therapeutics in a report on Thursday, February 22nd. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $309.44.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.